GRFS - Grifols extends losses as JPMorgan points to downside risk to consensus

There could be a downside to the consensus revenue and margins of Grifols (GRFS -4.0%) (OTCPK:GIKLY) (OTCPK:GIFLF), JPMorgan analyst James D Gordon warned, issuing the firm’s earnings preview for the Spanish plasma maker on Monday. After the comments, Grifols (NASDAQ:GRFS) ADRs have recorded the biggest intraday loss in more than two months in the U.S., and in the Madrid stock exchange, the company shares recovered from a sharp selloff in morning hours to end ~2% lower. Even as medical procedures postponed during the pandemic are set to make a comeback, the number of people donating blood each month fell by 10% at the end of 2021, The Wall Street Journal reported over the weekend, citing data from the American Red Cross. Grifols (GRFS) agrees. Announcing its 300th plasma donor center in the U.S., the company said in November that donations through the first few months of 2021 fell 11% from the past year

For further details see:

Grifols extends losses as JPMorgan points to downside risk to consensus